Regeneron's Phase III trial investigated cemdisiran and pozelimab as both monotherapies and in combination in gMG.

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient de ...

If you are part of the Venn diagram overlap of people who love both the nightmare-inducing ghosts of Phasmophobia and the surreal world of troubled author Alan Wake, then good news because a ...

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor ...

(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...

(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has a major impact on a person’s health and life. C3G has two forms: dense deposit ...

The alternative pathway (AP) plays a crucial role in triggering complement activation and promoting chronic inflammation. This study aims to investigate the longitudinal association between AP and ...

After a busy offseason, the Golden State Warriors have added several new pieces to their roster as they aim for another championship run. With Jonathan Kuminga’s contract situation finally settled, ...

Requirement Analysis: Identified the core operations required for the ALU: addition, subtraction, AND, OR, and NOT. Defined input and output specifications for the ALU. Two inputs A and B for binary ...